This revolutionary application is able to detect corona with 92% accuracy

The ResApp app is able to use machine learning to detect coronary heart disease with 92% accuracy by analyzing the user’s cough.

It seems impossible to imagine being able to find out about coronary heart disease simply by using an app on your smartphone and having a few coughs. However, according to the British Daily Mail, an app with 92% accuracy called ResApp will use machine learning to analyze your coughs, thereby detecting your coronavirus. 741 patients in the United States and India tested the program, of which 446 had Covid-19.

ResApp uses machine learning to determine if your cough indicates coronary heart disease.

People who tried the app first filled out a form for their symptoms and then installed the app on their phone to cough to diagnose coronary heart disease. The app correctly detected Covid-19 in 92% of these people.

To test whether the ResApp program could distinguish a cough from a cuvette from other problems such as asthma, pneumonia, and respiratory infections, 1007 patients with non-cuved respiratory problems were tested by the program, and in 90% of people, coronary heart disease was diagnosed correctly. Done by this application.

These results are quite promising, given that lateral flow tests can detect only about 72% of cases in asymptomatic patients and 58% in asymptomatic cases. Due to its high accuracy and portability, the developers believe that this program can be used in situations such as sports, entertainment, health care and travel, where repeated tests are required.

The ResApp app has also caught the attention of Pfizer, one of the world’s largest pharmaceutical companies and a maker of the Covid-19 vaccine. Last week, the company announced its intention to buy the program for $ 0.115 per share ($ 74.3 million in total) in cash. ResApp has also entered into a property rights agreement with Pfizer, under which $ 3 million will be paid in advance along with another $ 1 million through milestone payment (paid during project).

“Catherine Bennett, a member of the ResApp Scientific Advisory Board, said:

With rapid detection of Covid 19, the ResApp test is able to significantly reduce the number of rapid antigen and PCR tests, while maintaining patient monitoring. The simplicity, ease of use, and unlimited scalability of this test will be welcomed by public health officials around the world.

“ResApp CEO Tony Keating says:

We are very excited about the preliminary results of the Covid-19 detection program, using the recorded cough sound on a smartphone.

It listens to key cues when coughing and uses an algorithm to perform the diagnosis process with high accuracy.

“The Covid-19 tests in the UK are no longer as free as they used to be,” Keating added.

We intend to accelerate the commercialization process through immediate interaction with global regulators, and have already begun discussions with global health and technology companies with a view to bringing this product to market quickly.

He also talks about Pfizer’s partnership with his company:

Working with a company like Pfizer that is very meticulous in its work, as well as the offer to buy ResApp from this company, shows the trust in our team.

The ResApp program poses fewer environmental risks than PCR testing

“Many may believe that the release of this product may be delayed,” Keating said.

The World Health Organization (WHO) recently warned that the Covid-19 epidemic is not over, and that global health systems continue to face pressures and challenges. So we have to be prepared for the emergence of more dangerous strains of the virus.

Using a smartphone app that can accurately test the corona significantly reduces problems with current tests, such as test distribution, production costs, storage of tests in stores, doctors’ offices and hospitals, as well as the environmental impact of PCR and antigen samples. will give.

Most people these days know how to install and run an application. But following Quid’s test instructions at home is another story. One of the most popular home tests right now, BinaxNow, is made by Abbot. This test has an accuracy of about 84.6% in detecting Covid-19 and in 98.5% of cases it reports a negative result correctly.

In general, the ease and accuracy of using ResApp limits the corona test to having a cough near a cell phone. This app is not yet available to the public.